Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 7, 2021

Primary Completion Date

January 24, 2025

Study Completion Date

January 24, 2025

Conditions

Locally Advanced Solid Tumor

Interventions

DRUG

AN2025

oral administration

DRUG

AN0025

oral administration

DRUG

Atezolizumab 1200 mg in 20 ML Injection

infusion

Trial Locations (5)

NYU Grossman School of Medicine, New York

Florida Cancer Specialists - Lake Mary Cancer Center, Lake Mary

Stephenson Cancer Center, Oklahoma City

University of Colorado Cancer Center, Aurora

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors

lead

Adlai Nortye Biopharma Co., Ltd.

INDUSTRY

NCT04975958 - Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors | Biotech Hunter | Biotech Hunter